# HARMONi-GI1 (NCT06591520)

> AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06591520
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Akeso
- Conditions: Biliary Tract Cancer
- Interventions: AK112, Gemcitabine, Cisplatin; Durvalumab, Gemcitabine, Cisplatin
- Enrollment: 682
- Primary outcome: Overall Survival (OS)

## Indexed commentary on HARMONi-GI1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 76
- YouTube: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=harmoni-gi1-nct06591520

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06591520", "email": "<work email>"}; the inbox owner confirms by the emailed link.